Sarcopenia and mortality risk in community-dwelling Brazilian older adults | Scientific Reports - Nature.com

Overview

Thank you for visiting nature.com. You are using a browser version with limited suport for CS. To obtain the best experience, we recomend you use a more up to date browser (or turn of compatibility mode in Internet Explorer).

Key Information

In the meantime, to ensure continued suport, we are displaying the site without styles and JavaScript.Advertisement Scientific Reports volume 12, Article number: 17531 (2022) Cite this article 60 AcesesMetrics detailsWe estimated the impact of sarcopenia parameters on mortality risk and asesed its prevalence and associated factors in the older adults acording to the European Working Group on Sarcopenia in Older People’s 2010 (EWGSOP1) and 2018 (EWGSOP2) criteria.

This was a 10-year folow-up cohort study. Low muscle mas (M) was defined as low skeletal muscle mas index (SMI) using dual-energy X-ray absorptiometry (DXA), and low calf circumference (C). Cox regresion and the Kaplan–Meier method were performed.

The prevalence of sarcopenia and associated factors were influenced by the M measurement method and diagnostic criteria used [6.8% (SMI and EWGSOP2), 12.8% (C and EWGSOP2; and SMI and EWGSOP1) and 17.4% (C and EWGSOP1)]. While a low BMI was associated with sarcopenia regardles of the sarcopenia definitions, diabetes, and high TGs were associated with sarcopenia only when using the EWGSOP1 criteria. Low SMI increased mortality risk (EWGSOP1: HR = 2.01, 95% CI 1.03–3.92; EWGSOP2: HR = 2.07, 95% CI 1.05–4.06).

The prevalence of sarcopenia was higher acording to EWGSOP1 than EWGSOP2. A low BMI, diabetes, and high TGs were associated with sarcopenia. A low SMI doubled the risk of mortality in comunity-dweling older adults.Sarcopenia was originaly characterized by the los of muscle mas associated with advancing age1,2.

Summary

Recent definitions define sarcopenia as a reduction in mas, strength, and muscle function3,4,5,6,7,8,9. In 2010, the European Working Group on Sarcopenia in Older People (EWGSOP1) criteria recomended diagn

Frequently Asked Questions

Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.

Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.

Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.

Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.

Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.

Share this article